JP2021512071A5 - - Google Patents
Info
- Publication number
- JP2021512071A5 JP2021512071A5 JP2020540721A JP2020540721A JP2021512071A5 JP 2021512071 A5 JP2021512071 A5 JP 2021512071A5 JP 2020540721 A JP2020540721 A JP 2020540721A JP 2020540721 A JP2020540721 A JP 2020540721A JP 2021512071 A5 JP2021512071 A5 JP 2021512071A5
- Authority
- JP
- Japan
- Prior art keywords
- nanobodies
- composition
- epitopes
- ecm
- pathological
- Prior art date
Links
Priority Applications (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2024115829A JP2025003912A (ja) | 2018-01-25 | 2024-07-19 | 疾患におけるｅｃｍのナノボディに基づく画像化および標的化ならびに開発 |
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201862621811P | 2018-01-25 | 2018-01-25 | |
| US62/621,811 | 2018-01-25 | ||
| PCT/US2019/015290 WO2019148037A1 (en) | 2018-01-25 | 2019-01-25 | Nanobody based imaging and targeting of ecm in disease and development |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024115829A Division JP2025003912A (ja) | 2018-01-25 | 2024-07-19 | 疾患におけるｅｃｍのナノボディに基づく画像化および標的化ならびに開発 |
Publications (4)
| Publication Number | Publication Date |
|---|---|
| JP2021512071A JP2021512071A (ja) | 2021-05-13 |
| JP2021512071A5 true JP2021512071A5 (https=) | 2022-02-02 |
| JPWO2019148037A5 JPWO2019148037A5 (https=) | 2022-02-02 |
| JP7644441B2 JP7644441B2 (ja) | 2025-03-12 |
Family
ID=67299765
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020540721A Active JP7644441B2 (ja) | 2018-01-25 | 2019-01-25 | 疾患におけるｅｃｍのナノボディに基づく画像化および標的化ならびに開発 |
| JP2024115829A Pending JP2025003912A (ja) | 2018-01-25 | 2024-07-19 | 疾患におけるｅｃｍのナノボディに基づく画像化および標的化ならびに開発 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024115829A Pending JP2025003912A (ja) | 2018-01-25 | 2024-07-19 | 疾患におけるｅｃｍのナノボディに基づく画像化および標的化ならびに開発 |
Country Status (5)
| Country | Link |
|---|---|
| US (3) | US11597769B2 (https=) |
| EP (1) | EP3743443A4 (https=) |
| JP (2) | JP7644441B2 (https=) |
| CN (1) | CN112218890A (https=) |
| WO (1) | WO2019148037A1 (https=) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN112218890A (zh) | 2018-01-25 | 2021-01-12 | 麻省理工学院 | 在疾病和发展中基于纳米抗体的ecm成像和靶向 |
| EP4047016A1 (en) | 2021-02-19 | 2022-08-24 | Université de Strasbourg | Anti-tenascin-c (tnc) single-domain antibodies (nanobodies) and use thereof |
| CN113151177B (zh) * | 2021-05-21 | 2023-11-03 | 四川大学华西医院 | 乳腺或乳腺癌组织脱细胞基质及其制备方法和用途 |
| US20240238451A1 (en) * | 2021-05-28 | 2024-07-18 | Albert Einstein College Of Medicine | Single-domain antigen-dependent antibody-like fusion proteins |
| CN119095870A (zh) * | 2022-03-21 | 2024-12-06 | 香港理工大学 | 肽双特异性抗体及其制备方法和应用 |
| CN117624360A (zh) * | 2022-08-26 | 2024-03-01 | 南京融捷康生物科技有限公司 | 一种抗trem2的单域抗体及其用途 |
| IL319909A (en) * | 2022-12-30 | 2025-05-01 | Remegen Shanghai Co Ltd | Bispecific antibody and its use |
| WO2025149667A1 (en) | 2024-01-12 | 2025-07-17 | Pheon Therapeutics Ltd | Antibody drug conjugates and uses thereof |
| WO2025175132A1 (en) * | 2024-02-15 | 2025-08-21 | Board Of Regents, The University Of Texas System | Methods for selecting triple-negative breast cancer patients for targeted therapy using tumor-specific total mrna expression |
Family Cites Families (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2000076456A2 (en) * | 1999-06-14 | 2000-12-21 | The General Hospital Corporation | Modulators of fibrosis |
| US9320792B2 (en) * | 2002-11-08 | 2016-04-26 | Ablynx N.V. | Pulmonary administration of immunoglobulin single variable domains and constructs thereof |
| CA2723842A1 (en) * | 2008-05-09 | 2009-11-12 | Peter Vanlandschoot | Amino acid sequences directed against integrins and uses thereof |
| EP2970426B1 (en) * | 2013-03-15 | 2019-08-28 | Michael C. Milone | Targeting cytotoxic cells with chimeric receptors for adoptive immunotherapy |
| CN109563141A (zh) * | 2016-05-13 | 2019-04-02 | 奥里尼斯生物科学公司 | 对非细胞结构的治疗性靶向 |
| MX2019000641A (es) * | 2016-07-15 | 2019-06-10 | Poseida Therapeutics Inc | Composiciones de mucina1-receptor de antigeno quimerico y metodos para su uso. |
| CN112218890A (zh) | 2018-01-25 | 2021-01-12 | 麻省理工学院 | 在疾病和发展中基于纳米抗体的ecm成像和靶向 |
-
2019
- 2019-01-25 CN CN201980019075.5A patent/CN112218890A/zh active Pending
- 2019-01-25 JP JP2020540721A patent/JP7644441B2/ja active Active
- 2019-01-25 EP EP19743635.5A patent/EP3743443A4/en active Pending
- 2019-01-25 US US16/258,457 patent/US11597769B2/en active Active
- 2019-01-25 WO PCT/US2019/015290 patent/WO2019148037A1/en not_active Ceased
-
2023
- 2023-02-28 US US18/175,786 patent/US12454576B2/en active Active
-
2024
- 2024-07-19 JP JP2024115829A patent/JP2025003912A/ja active Pending
-
2025
- 2025-09-30 US US19/346,100 patent/US20260028406A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2021512071A5 (https=) | ||
| JP2023116721A5 (https=) | ||
| JP2021184963A5 (https=) | ||
| JP2021028398A5 (https=) | ||
| CN113316591A (zh) | Cd73抗体及其制备方法和应用 | |
| JP2022116141A5 (https=) | ||
| JP2011506530A5 (https=) | ||
| JP2012509886A5 (https=) | ||
| JP2011182796A5 (https=) | ||
| JP2016512050A5 (https=) | ||
| DK2215119T3 (da) | Monoklonale antistoffer der binder til HGM-CSF og medicinske sammensætninger omfattende de samme. | |
| JP2008515616A5 (https=) | ||
| JP2012524702A5 (https=) | ||
| JP2010532504A5 (https=) | ||
| JPWO2022202973A5 (https=) | ||
| JP2013501834A5 (https=) | ||
| JP2020504434A5 (https=) | ||
| JP2023100857A5 (https=) | ||
| JP2022122912A5 (https=) | ||
| JP2023156274A5 (https=) | ||
| JP2009263366A5 (https=) | ||
| JP2016153446A5 (https=) | ||
| JP2026010057A5 (https=) | ||
| JP2023097358A5 (https=) | ||
| JP2025123368A5 (https=) |